This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 202| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2231 | TP73-AS1 | LncRNA | Human | Upregulated in HCC (with more than 2 fold change) | Diagnostic and Prognostic | HCC v/s Normal; associated with worse clinicopathological features, poorer prognosis and shorter survival | p < 0.001 | Tissue | 28403886 |
| 2234 | CCAT2 | LncRNA | Human | Upregulated in HCC | Prognostic | HCC v/s Normal; associated with poor survival in HCC patients | p < 0.01 | Tissue | 28280353 |
| 2235 | SNHG20 | LncRNA | Human | Upregulated in HCC | Prognostic | HCC v/s Normal; associated with survival of patients | p < 0.001 | Tissue | 27053960 |
| 2238 | CCAT1 | LncRNA | Human | Upregulated in HCC | Prognostic | HCC v/s Normal; correlated with tumor size, microvascular invasion and poor prognosis | p < 0.001 | Tissue | 25884472 |
| 2239 | lncCAMTA1 | LncRNA | Human | Upregulated in HCC and lncCAMTA1 is increased in HCC and indicates poor outcome. | Prognostic | HCC v/s Normal; associated with poor recurrence free survival and overall survival of patients | p < 0.01 | Tissue | 27669232 |
| 2240 | lncRNA-hPVT1 | LncRNA | Human | Upregulated in HCC and higher hPVT1 expression levels in HCC tissues significantly correlated with markedly reduced recurrence-free survival | Diagnostic and Prognostic | HCC v/s Normal; associated with recurrence and survival in patients | p < 0.001 | Tissue | 25043274 |
| 2241 | DANCR | LncRNA | Human | Upregulated in HCC | Diagnostic and Prognostic | HCC v/s Normal/Cirrhosis/CHB;associated with metastasis of patients | p < 0.001 | Plasma | 27919960 |
| 2243 | XLOC_014172 | LncRNA | Human | Upregulated in HCC with Fold change >2.1 | Diagnostic and Prognostic | HCC v/s Normal; associated with metastatsis of patients | p < 0.01 | Plasma | 25714016 |
| 2244 | LOC149086 | LncRNA | Human | Upregulated in HCC with Fold change >2.0 | Diagnostic and Prognostic | HCC v/s Normal; associated with metastatsis of patients | p < 0.01 | Plasma | 25714016 |
| 2245 | RP11-160H22.5, XLOC_014172, LOC149086 | LncRNA | Human | Upregulated in HCC with Fold change >2.0 | Diagnostic and Prognostic | HCC v/s Normal; associated with metastatsis of patients | p < 0.01 | Plasma | 25714016 |
| 2260 | CDK4 | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2261 | Bax | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2262 | NOTCH4 | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2263 | ISGF3G | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2264 | TNF | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2265 | VISA | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
| 2266 | AURKB-Sv2 variant | RNAs | Human | Upregulated in metastatic HCC than primary HCC and Absent in normal | Prognostic | Metastatic HCC v/s Primary HCC; correlated with a poor outcome and short disease-free period | p < 0.01 | Cell line and Tissue | 19134008 |
| 2269 | Phosphoserine aminotransferase | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 3.8) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2270 | IFP53/Tryptophanyl-Trna synthetase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.27) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2271 | Peroxiredoxin 3 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.82) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2272 | GRP94 (Tumor rejection antigen 1) | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.59) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2273 | Annexin A1 (Phospholipase A2 inhibitory protein) | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.52) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2274 | Superoxide dismutase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.44) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2275 | Annexin A2 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.42) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2276 | Annexin A4 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.6) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2277 | L-lactate dehydrogenase B chain | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.61) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2278 | Cyclophilin B (Peptidyl-prolyl cis-trans isomerase B) | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.53) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2279 | ORP150 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.59) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2280 | Vinculin | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.82) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2281 | Flavin reductase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.52) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2282 | Stathmin | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.56) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2283 | Protein kinase C inhibitor protein-1 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 2.7) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2284 | Heterogeneous nuclear ribonucleoprotein A2/B1 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.55) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2285 | 26S proteasome non-ATPase regulatory subunit 8 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2286 | Glutamine amidotransferase | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.69) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2287 | Phosphoglycerate kinase 1 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.57) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2288 | TCP-1 chaperonin cofactor A | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.57) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2289 | TCP-1-gamma | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2290 | Multidrug resistance-associ ated protein MGr1-Ag | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.51) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2291 | Nuclear chloride ion channel 27 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2303 | CD24 | RNAs | Human | Upregulated in the high-risk group | Prognostic | Early recurrence of HCC v/s Late recurrence of HCC | p < 0.001 | Tissue | 18381945 |
| 2317 | NDRG2 | Protein and RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic and Prognostic | HCC v/s cirrhosis/healthy/non-tumor HCC; associated with recurrence and tumor grade | p < 0.05 | Tissue | 18519680 |
| 2321 | TGF beta | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
| 2322 | Myc | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
| 2323 | LOC388796, A_32_P406142, SAFB, MKL1, TNKS1BP1, PMM2, PPP2R5C, SAFB2, GATA4, RASD1, KIAA1967, | RNAs | Human | over expressed in subjects with fastest recurrence | Prognostic | early occurrence v/s late recurrence | p < 0.0001 | Tissue | 20380719 |
| 2324 | ID2 | Protein and RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.4) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.005 | Tissue | 17088983 |
| 2325 | API5 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.49) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2326 | CTAG1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.36) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2327 | NOLA2 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.34) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2328 | DKFZP566D193 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.3) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |